These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24187841)

  • 1. [Pharmacodynamics and pharmacokinetics of batroxobin in Beagle dog].
    Zheng ZH; Zhu XX; Gan H; Gu RL; Wu ZN; Meng ZY; Dou GF
    Yao Xue Xue Bao; 2013 Aug; 48(8):1307-11. PubMed ID: 24187841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulant Effect and Tolerability of Yeast-Produced Recombinant Batroxobin in Healthy Adult Subjects.
    Choi SK; Kim CW; Kim JT; Seomun Y; Park MS; Kim CO
    Clin Drug Investig; 2018 Sep; 38(9):829-835. PubMed ID: 29978322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies of pharmacokinetics and anticoagulatory effect in rats after oral administration of Frankincense and its processed products.
    Pan YN; Liang XX; Niu LY; Wang YN; Tong X; Hua HM; Zheng J; Meng DY; Liu XQ
    J Ethnopharmacol; 2015 Aug; 172():118-23. PubMed ID: 26117531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic change of coagulation and anticoagulation markers of patients with acute cerebral infarction during intravenous urokinase thrombolysis.
    Ji X; Meng R; Zhou J; Ling F; Jia J
    Neurol Res; 2006 Jan; 28(1):46-9. PubMed ID: 16464362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in mRNA levels of fibrinogen subunit polypeptides in rats defibrinogenated with batroxobin.
    Iwai S; Okazaki M; Kiuchi Y; Oguchi K
    Thromb Res; 1999 Dec; 96(6):421-6. PubMed ID: 10632464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of 8 and 24-h storage of whole blood at ambient temperature on prothrombin time, activated partial thromboplastin time, fibrinogen, thrombin time, antithrombin and D-dimer.
    Kemkes-Matthes B; Fischer R; Peetz D
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):215-20. PubMed ID: 21297453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of fibrinogen degradation products on thrombin time, activated partial thromboplastin time and prothrombin time of canine plasma.
    Mischke R; Wolling H
    Haemostasis; 2000; 30(3):123-30. PubMed ID: 11014962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro effects of hemocoagulase atrix and its effective components on blood coagulation of patients with bleeding disorders].
    Wang RJ; Wang ZY; Jiang MH; Zhang W; Cao LJ; Sun XH; Zhang J; Bai X; Ruan CG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Apr; 20(2):376-80. PubMed ID: 22541102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
    Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
    J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defibrinogenating enzymes.
    Bell WR
    Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of hydrogen sulfide on tissue factor-induced disseminated intravascular coagulation in rabbits].
    Lu X; Li W; Wang G; Wang Q; Jiang Y; Gao J; Zhao X; Xu L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2015 Feb; 27(2):92-6. PubMed ID: 25665605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of batroxobin with activated polyethylene glycol: reduction of binding ability towards anti-batroxobin antibody and retention of defibrinogenation activity in circulation of preimmunized dogs.
    Nishimura H; Takahashi K; Sakurai K; Fujinuma K; Imamura Y; Ooba M; Inada Y
    Life Sci; 1983 Oct; 33(15):1467-73. PubMed ID: 6353117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of plasma fibrinogen level-based defibrase therapy in patients with acute cerebral infarction].
    Cai XB; Zhu ZS; Zhang MZ; Guo J; Wang HL
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2124-7. PubMed ID: 19861283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses.
    Bäumer W; Herrling GM; Feige K
    BMC Vet Res; 2013 Aug; 9():158. PubMed ID: 23938183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion.
    Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F
    Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemostyptic effects of batroxobin with regard to hirudin treatment.
    Markwardt F; Kaiser B; Richter M
    Thromb Res; 1992 Dec; 68(6):475-82. PubMed ID: 1341058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prothrombin time, activated partial thromboplastin time, and fibrinogen concentration in blood samples collected via an intravenous catheter versus direct venipuncture in dogs.
    Maeckelbergh VA; Acierno MJ
    Am J Vet Res; 2008 Jul; 69(7):868-73. PubMed ID: 18593235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin and thrombolytic effects of a new antithrombin agent: angioscopic and angiographic comparison with heparin or batroxobin.
    Tomaru T; Nakamura F; Miwa AY; Fujimori Y; Omata M; Okada R; Uchida Y
    J Interv Cardiol; 1994 Oct; 7(5):409-19. PubMed ID: 10155190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defibrinogenating effect of batroxobin (Defibrase) in rats and inhibition of migration of human vascular smooth muscle cells by the plasma of batroxobin-treated rats in vitro.
    Wang DS; Hanamoto M; Fang F; Ohba M; Ishii M; Kimura F; Higaki E; Senga H
    Atherosclerosis; 2001 May; 156(1):73-80. PubMed ID: 11368999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Johansson LC; Frison L; Logren U; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(4):381-92. PubMed ID: 12648028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.